Evidence map›Paper›PMID 30218573›Full record

ArticleEuropean journal of immunology2018

TMP778, a selective inhibitor of RORγt, suppresses experimental autoimmune uveitis development, but affects both Th17 and Th1 cell populations.

Cancan Lyu, So Jin Bing, Wambui S Wandu, Biying Xu, Guangpu Shi, Samuel J Hinshaw, Mercedes Lobera, Rachel R Caspi, Lin Lu, Jianfei Yang and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. CD4International journal of molecular sciences · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Cancan LyuLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
So Jin BingLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Wambui S WanduLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Biying XuLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Guangpu ShiLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Samuel J HinshawLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Mercedes LoberaGlaxoSmithKline, Cambridge, MA, USA.
Rachel R CaspiLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Lin LuState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.
Jianfei YangGlaxoSmithKline, Cambridge, MA, USA.
Igal GeryLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9953-4859
National Institutes of Health · USGlaxoSmithKline (India) · INSun Yat-sen University · CN

Funding

Genetic, Cellular and Molecular Mechanisms in Autoimmunity to RetinaZIAEY000184 · NEI · NATIONAL EYE INSTITUTE · PI CASPI, RACHEL R. · 2009 to 2025
$51.7M
IMMUNE RESPONSES TO OCULAR ANTIGENSZ01EY000069 · NEI · NATIONAL EYE INSTITUTE · PI GERY, IGAL · 1985 to 2008
$2.7M
Intramural NIH HHS Z01 EY000069NIH HHS
6 · The paper itself

Abstract

Experimental autoimmune uveitis (EAU), an animal model for severe intraocular inflammatory eye diseases, is mediated by both Th1 and Th17 cells. Here, we examined the capacity of TMP778, a selective inhibitor of RORγt, to inhibit the development of EAU, as well as the related immune responses. EAU was induced in B10.A mice by immunization with interphotoreceptor retinoid-binding protein (IRBP). Treatment with TMP778 significantly inhibited the development of EAU, determined by histological examination. In addition, the treatment suppressed the cellular immune response to IRBP, determined by reduced production of IL-17 and IFN-γ, as well as lower percentages of lymphocytes expressing these cytokines, as compared to vehicle-treated controls. The inhibition of IFN-γ expression by TMP778 is unexpected in view of this compound being a selective inhibitor of RORγt. The observation was further confirmed by the finding of reduced expression of the T-bet (Tbx21) gene, the transcription factor for IFN-γ, by cells of TMP778-treated mice. Thus, these data demonstrate the capacity of TMP778 to inhibit pathogenic autoimmunity in the eye and shed new light on its mode of action in vivo.

Indexed as

AnimalsAutoimmune DiseasesCytokinesDisease Models, AnimalEye ProteinsFemaleHeterocyclic Compounds, 4 or More RingsInterferon-gammaInterleukin-17MiceNuclear Receptor Subfamily 1, Group F, Member 3Retinol-Binding ProteinsRetinol-Binding Proteins, InterstitialT-bet Transcription FactorT-Box Domain ProteinsTh17 CellsCytokinesEye ProteinsHeterocyclic Compounds, 4 or More RingsInterferon-gammaInterleukin-17Nuclear Receptor Subfamily 1, Group F, Member 3Retinol-Binding ProteinsRetinol-Binding Proteins, InterstitialT-bet Transcription FactorT-Box Domain ProteinsTMP778Experimental autoimmune uveitisInhibitionRORγtTh17 cellsTh1 cellsTMP778

Identifiers

PMID30218573
PMCPMC6392427
OpenAlexW2889562046

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.